Progress of targeted therapy for acute myeloid leukemia

VernacularTitle:急性髓系白血病靶向治疗研究进展
Author: Qiannan YANG ¹ ; Xiang ZHANG ; Yi FAN ; Depei WU
Author Information

1. 国家血液系统疾病临床医学研究中心　江苏省血液研究所　苏州大学附属第一医院，苏州　215006
Keywords: Leukemia, myeloid, acute; Targeted therapy; Precision diagnosis and treatment; Treatment outcome
From: Journal of Leukemia & Lymphoma 2025;34(9):565-569
CountryChina
Language:Chinese
Abstract: Acute myeloid leukemia (AML) is the most common type of leukemia in adults, which is characterized by a complex genetic background, high heterogeneity, and poor prognosis. With the advance in molecular biology and novel drug development, the pathogenesis of AML has been further elucidated. Some novel therapies for AML have been widely applied, including epigenetic modulators, molecular targeted agents, monoclonal antibodies and antibody-drug conjugates, many of which have been approved and incorporated into treatment guidelines. Targeted monotherapy or combination therapies are precise and show mild adverse effects. Currently, whether targeted therapies can challenge conventional treatment methods for AML patients has become a research focus. This paper reviews the recent progress of targeted therapies for AML (non-acute promyelocytic leukemia).